Q1UE34 Stock Overview
Provides diagnostic testing and services in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Quest Diagnostics Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$456.51 |
| 52 Week High | US$456.51 |
| 52 Week Low | US$307.83 |
| Beta | 0.89 |
| 11 Month Change | 9.21% |
| 3 Month Change | 9.21% |
| 1 Year Change | n/a |
| 33 Year Change | 16.93% |
| 5 Year Change | n/a |
| Change since IPO | 97.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| Q1UE34 | BR Healthcare | BR Market | |
|---|---|---|---|
| 7D | 0% | -2.1% | -0.6% |
| 1Y | n/a | -4.1% | 5.1% |
Return vs Industry: Insufficient data to determine how Q1UE34 performed against the BR Healthcare industry.
Return vs Market: Insufficient data to determine how Q1UE34 performed against the BR Market.
Price Volatility
| Q1UE34 volatility | |
|---|---|
| Q1UE34 Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 6.4% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in BR Market | 9.1% |
| 10% least volatile stocks in BR Market | 2.3% |
Stable Share Price: Q1UE34's share price has been volatile over the past 3 months compared to the BR market.
Volatility Over Time: Insufficient data to determine Q1UE34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1967 | 44,000 | Jim Davis | www.questdiagnostics.com |
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals.
Quest Diagnostics Incorporated Fundamentals Summary
| Q1UE34 fundamental statistics | |
|---|---|
| Market cap | R$100.03b |
| Earnings (TTM) | R$4.84b |
| Revenue (TTM) | R$55.05b |
20.6x
P/E Ratio1.8x
P/S RatioIs Q1UE34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| Q1UE34 income statement (TTM) | |
|---|---|
| Revenue | US$9.54b |
| Cost of Revenue | US$6.39b |
| Gross Profit | US$3.15b |
| Other Expenses | US$2.31b |
| Earnings | US$838.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.51 |
| Gross Margin | 32.97% |
| Net Profit Margin | 8.79% |
| Debt/Equity Ratio | 90.3% |
How did Q1UE34 perform over the long term?
See historical performance and comparison